ADMA Shares Plunge 42.5% YTD Following Short Seller Report

ADMA Biologics has experienced a sharp decline in its share price, falling 42.5% year-to-date. The downward pressure intensified following the release of a short seller report targeting the company, which typically triggers rapid sell-offs as investors react to allegations of overvaluation or operational flaws. The volatility comes at a critical juncture as the company attempts to scale its operations and solidify its market position. While the short report has damaged investor sentiment in the immediate term, some analysts are looking toward the company's internal performance metrics for signs of stability. Contrasting the stock's poor price performance, the company reports strong demand for its product, Asceniv. Management has pointed toward rising revenues and expanding margins as key indicators of operational health and long-term viability. Traders are currently weighing the bearish claims of the short report against these reported growth metrics. The stock's ability to recover will likely depend on the company's ability to refute the short seller's claims through upcoming financial disclosures and sustained product demand.